Cost-utility Study of Cognitive-behavioral Management of Auditory Hallucinations in Schizophrenic Disorder

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age15-45
SponsorUniversity Hospital, Montpellier

About this trial

The aim of the study is to assess the effectiveness and costs of a cognitive-behavioral treatment (CBT) for auditory hallucinations (psychotherapy) as an adjunct to usual care, comparing it to the effectiveness and costs of usual care alone. Usual care is defined as the use of medication, regular consultations with your psychiatrist, and, if necessary, day hospital care.

The study plans to include 240 participants across several hospitals in France (multicenter study). Each participant will be randomly assigned to either the intervention group (cognitive-behavioral therapy) or the control group (usual treatment). Participants assigned to the control group will have the opportunity to receive therapy for auditory verbal hallucinations (AVHs) after the study.

After an initial inclusion assessment (V0), the participant will be randomly assigned to one of the two groups after the V1 assessment. Additional evaluations will be conducted after inclusion at 4 months, 8 months, and 12 months.The evaluations consist of questionnaires to assess intensity and severity of AVHs / beliefs related to AVHs, clinical status, well-being, depression, suicidal thoughts, quality of life, functioning (mobility/autonomy/pain, etc.), sleep and costs related to care.

At Visit 1, after obtaining consent for participation in the study on behalf of your ward, the investigator will also collect their social security number, full date of birth, and gender, which will allow us to gather information on actual healthcare consumption from the healthcare system.

The VOICES intervention will consist of 16 one-hour individual sessions (one session per week over a 16-week period), divided into several types of intervention (modules) that have been independently proven to treat AVHs. The VOICES intervention is modular, personalized, and incorporates patient preference. Following an initial clinical assessment, patients will be offered first the GIVE intervention (8 sessions) and subsequently a choice of treatment modules, delivered by a clinical psychologist.

After this first module (GiVE Intervention), three other intervention modules will be proposed. These three additional modules comprise seven sessions each. One additional relapse prevention sessions will be scheduled at the end of these modules.

\- The GiVE intervention is divided into five modules: (1) Coping - exploring ways to manage voices; (2) Me - targeting negative beliefs about the self; (3) My Voices - targeting unhelpful beliefs about voices; (4) My Relationships - improving assertiveness in difficult relationships; and (5) Looking to the Future - making plans to continue the use of new skills. Modules 2, 3 and 4 were each offered over two sessions (six sessions in total), and modules 1 and 5 were each one session long.

After the GivE intervention three modules will be offered will be :

* "Relating CBT" is based on a large body of research which has shown that voice hearers personify their voices and establish relationships with them, which largely correspond to the relationships they generally establish with the people around them. The aim of relational therapy will be to modify this relationship and enable the voice hearer to develop assertive and balanced behaviours towards them. * The individual "Mindfulness Program for Voices" will be delivered individually and will include guided mindfulness exercises, complemented by discussions aimed at cultivating mindful responses as alternatives to automatic or habitual reactions.

* Imagery rescripting for distressing voices will consist of a series of targeted imagery-based interventions guided by a micro-formulation approach. This method will focus on the identification and transformation of discrete, emotionally salient mental images linked to specif distressing experiences

All participants will receive medical monitoring, and the treatment will be the same in both groups. No treatment will be prohibited if deemed necessary for your health. At any time, participants have the right to withdraw their consent and stop participating in the research, without any change to their care, as long as the patient's condition does not require otherwise.

The expected benefits for participants are a significant improvement in the symptoms as well as psychosocial functioning, leading to greater autonomy in daily life and an improved quality of life. In the control group, the follow-up will likely be more attentive than usual, with regular evaluations. In any case, there is no loss of opportunity for the participant regardless of the group assignment. Additionally, random assignment to the control group allows participants to benefit from AVH therapy after the study.

When the research is completed, participants will be informed of the overall results by the investigator as soon as they are available, if wished.

Participation in this research will not incur any additional costs compared to the usual follow-up for this condition.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with a diagnosis of schizophrenic disorder according to DSM 5 as assessed by the investigating psychiatrist during the screening medical examination

Age between 15 and 45 years inclusive

Patients hearing AVHs for at least 3 months

Patient with a score of at least 2 on the distress intensity item of the hallucinations subscale of the Psychotic Symptom Rating Scale (PSYRATS-AH).

Disqualifiers

Patients hospitalized full-time for acute decompensation of their schizophrenic disorder

Patients with a history of severe head trauma and/or neurological pathology with cognitive impact

Patients with a characterized depressive state (Calgary scale score>9)

Patients unable to understand, speak and read French

Trial design

Design model

Parallel

Treatments tested in this trial

  • Cognitive and behavioral therapy for auditory hallucinations

    Other intervention

    Consists of 16 one-hour individual sessions (one session per week over a 16-week period) of cognitive behavioral therapy, divided into three types of interventions (modules) that have been independently proven to be effective in the management of auditory hallucinations.

  • Usual treatment

    Other intervention

    Consists of an antipsychotic medication treatment (including dosage changes and molecule changes.), regular consultation with a psychiatrist (once a month on average), and if necessary, one-off psychological support or family interventions not including specific CBT for positive symptoms

Treatment groups

240 Participants
are divided into 2 treatment groups
Group A: Cognitive and behavioral therapy for auditory hallucinationsExperimental treatment 1 intervention
Group B: Usual treatmentActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Incremental cost-utility ratio

Incremental cost-utility ratio (ICUR) at 12 months, of the management of auditory hallucinations by CBT compared to usual treatment. The preferred outcome criterion is the QALY (Quality Adjusted Life Years) unit of measurement of the duration of life weighted by the quality of life related to health (HAS 2020), calculated from the utilities derived from the EuroQuality of life 5 dimensions questionnaire (EQ5D-5L).

Time frame
Baseline, 4 months, 8 months, 12 months

Secondary outcomes

1

Distress associated with AVHs and frequency

Using the Psychotic Symptom Rating Scales - Auditory Hallucinations (PSYRATS-AH; Haddock et al., 1999; Favrod et al., 2012 for French validation), a hetero-questionnaire consisting of 11 items designed to measure the severity of various dimensions of the auditory hallucination experience. The items are grouped into four factors: distress (negative content, distress, and control), frequency (frequency, duration, and disruption), attribution (location and origin of the auditory hallucinations), and intensity of sound. Each item is rated on a scale from 0 ("not at all") to 4 ("always"). The total score ranges from 0 to 44.

Time frame
Baseline, for intervention group 6 weeks to 11 weeks, 4 months, 8 months, 12 months
2

Beliefs about voices

Using The Beliefs About Voices Questionnaire (BAVQ-R, Chadwick and al, 2000) a self-report questionnaire that assesses beliefs, emotional, and behavioral consequences related to auditory hallucinations (AHs). It initially contains 35 items, each rated from 0 ("strongly disagree") to 3 ("strongly agree"), and is divided into 5 subscales: Power, Malevolence, Benevolence, Resistance, and Engagement. We will consider the total score for the four subscales: Power, Malevolence, Resistance, and Engagement (total score ranging from 0 to 12).

Time frame
Baseline, months 4, 8 and 12
3

Maastricht Semi-structured Interview

The Maastricht Semi-structured Interview, developed by Romme and Escher (2000), is a precursor to the early work on the experience of AVHs in the Netherlands. It allows for the assessment of this phenomenological experience through a variety of individual variables such as intensity, volume, and number of AVHs, while also addressing the individual's environmental spheres and potential journey through different psychiatric care services.

Time frame
Baseline only for The Maastricht interview
4

Auditory Hallucination Rating Scale

Auditory Hallucination Rating Scale (AHRS), French validation by Dondé et al., 2020. This scale includes 7 questions regarding the frequency, intensity, or intentional valence of AVHs.

Time frame
Baseline, months 4, 8 and 12

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital, Montpellier

Lead sponsor

Assistance Publique Hopitaux De Marseille

Collaborator

Centre Hospitalier Universitaire de Nīmes

Collaborator

Centre Hospitalier de Béziers

Collaborator

University Hospital, Clermont-Ferrand

Collaborator

Assistance Publique - Hôpitaux de Paris

Collaborator

University Hospital, Strasbourg, France

Collaborator

This trial is not recruiting at the moment. You can still explore other options: